Skip to main content
Kent Academic Repository

A review of the safety and tolerability of sertindole

Hale, Anthony S. (1998) A review of the safety and tolerability of sertindole. International Clinical Psychopharmacology, 13 . S65-S70. ISSN 0268-1315. (doi:10.1097/00004850-199803003-00011) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:17793)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided.
Official URL:


The safety and efficacy of sertindole have been established in three double-blind randomized controlled studies conducted in the United States, North America and Europe. In these three studies the tendency for sertindole to cause extrapyramidal side effects (EPS), a critical factor affecting compliance, was investigated. At 12-24 mg/day, sertindole was associated with placebo levels of EPS, which were significantly lower than for all doses of haloperidol. In the European study, 24 mg sertindole demonstrated slightly, but statistically significantly, more EPS than 8 mg (P = 0.05). However, the incidence of EPS-related events was comparable with that reported for placebo in the United States and North American studies. The frequency of use of anti-EPS medication was also comparable in the sertindole and placebo groups. Slight prolongation of the Q-T interval was seen with sertindole in early clinical trials. Although no patients reported any clinical problems related to Q-T prolongation in these three studies, its use is contraindicated in patients suffering from underlying cardiac diseases or hypokalaemia and in those patients undergoing concomitant treatment with other medication known to prolong the Q-T interval. Most of the other adverse events reported for sertindole are related to its alpha(1) antagonistic activity. Int Clin Psychopharmacol 13 (suppl 3):S65-S70

Item Type: Article
DOI/Identification number: 10.1097/00004850-199803003-00011
Additional information: Symposium on New Treatment Strategies and Novel Antipsychotics - a New Window of Opportunities ROME, ITALY, OCT 03-04, 1997
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Divisions > Division for the Study of Law, Society and Social Justice > School of Social Policy, Sociology and Social Research
Depositing User: R.F. Xu
Date Deposited: 09 Jul 2009 08:25 UTC
Last Modified: 09 Mar 2023 11:31 UTC
Resource URI: (The current URI for this page, for reference purposes)

University of Kent Author Information

Hale, Anthony S..

Creator's ORCID:
CReDIT Contributor Roles:
  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.